Senior professionals reviewing a pharmaceutical risk matrix, audit records and neutral sample packaging
Governance control

Representative governance and quality oversight

01Board02Quality03Claims04Audit trail
Governance

Accountability for a company preparing to operate in a regulated market.

NovaPharm separates statutory governance, owner-approved executive responsibilities and regulated appointments so that a public title does not imply unevidenced authority.

Statutory board

Four active directors are recorded at Companies House.

Executive responsibilities follow the owner-approved leadership record dated 7 August 2026; statutory office remains separately evidenced at Companies House.

Vishal ChakravartyChief Executive OfficerFounder and statutory directorPrabhakar Vitthal LahareChief Operating OfficerFounder and statutory directorDr Girish Shantilal AchliyaChief Scientific OfficerStatutory directorDr Helly PanchalChief Medical DirectorStatutory director

Source: Companies House officer record, checked 11 July 2026. Companies House notes that filed information is not independently verified by the service.

Dr Nishita TrivediChief Technology Officer and Responsible PersonExecutive responsibility and regulated appointment; not a statutory director. Formal appointment documentation remains controlled evidence pending.
Claims governance

A planned capability is not a current authorisation.

Public copy, product records and structured data use status language for regulatory preparation, partner development and technology roadmap items.

  • No WDA(H) claim without official verification
  • No PLPI licence or available-stock claim without product evidence
  • No NHS supply or framework claim without confirmation
  • No partner-logo or scope claim without permission
  • No roadmap technology presented as deployed
Start a qualified conversation

Bring a governed pharmaceutical opportunity to NovaPharm.

Discuss a partnershipOpen an account